ASTELLAS PHARMA INC | TalkMarkets

Latest Posts

Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal

Article By: ChinaBio® Today

Sunday, December 31, 2023 11:00 AM EDT

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program. Initially, Elpiscience will receive up to $37 million.

In this article: AZN, ALPMY, GRCL, LIAN, IVBXF

Read

Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas

Article By: ChinaBio® Today

Saturday, June 17, 2023 3:00 PM EDT

Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates for hypercholesterolemia and metabolic diseases.

In this article: ALPMY Also: AZN, IVBXF, CHSYF

Read

4 No-Brainer Pharmaceutical Stocks To Buy In October

Article By: StockNews

Monday, September 27, 2021 9:00 PM EDT

While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical industry.

In this article: ALPMY, AZN, GSK, JNJ

Read

The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO

Article By: Benzinga

Friday, August 21, 2020 7:41 AM EDT

Covering today's biggest news in biotech, including upcoming IPO's and which stocks are hitting their 52 week high and lows.

In this article: XERS, AZN, JNJ, PFE, ALPMY, SRNE, EARS, GMAB, BNTX, TLSA, RNLX, KYMR Also: UBX, TRIL, TNDM, MMSI, PACB, REPH, FLGT, FBIO, OTIC, TLGT, SWAV, ALEC, ITRM, CSTL, ATXI, TXG, SONN, KROS, CRDF, NRIX, POAI, PCVX, ENTX, HRMY, HSTO, INBX, NAOV

Read